PROPEL represents a medical breakthrough clinically proven to improve surgical outcomes for chronic sinusitis sufferers.1

PROPEL is the first and only device clinically shown to keep the sinuses open after surgery, precisely deliver anti-inflammatory medication directly into the healing tissues, and then dissolve. The innovative sinus stent decreases post-operative scarring and inflammation, reducing the need for additional surgical procedures as well as oral steroids1 and their potential side effects. At the same time, PROPEL’s spring-like, lightweight design means patients usually cannot even tell that it is there.

1  Han  JK,  Marple  BF,  Smith  TL  et  al.  IFAR.2012;  2:271-­‐279.   The  PROPEL  sinus  implant  is  intended  for  use  in  pa7ents  ≥  18  years  of  age  following  ethmoid  sinus  surgery  to  maintain  the  sinus  opening.  This  product  is  not  intended  for  people  who  are  allergic  to  the  drug  (mometasone  furoate)  or  to  certain  polymers.  Safety  and  effec7veness  of  the  implant  in  pregnant  or  nursing  females  has  not  been  studied.  Risks  may  include  pain/pressure,  movement  of  the  implant  (within  or  out  of  the  sinus)  and  possible  side  effects  of  the  drug.  The  most  common  side  effects  in  clinical  studies  were  infec7on,  headache  and  nose  bleed.  For  more  informa7on  on  the  risks  and  benefits  of  PROPEL,  please  talk  to  your  doctor.  The  FDA  approved  labeling  can  be  found  at  www.PROPELOPENS.com.  Rx  only.    For  addi7onal  pa7ent  informa7on  regarding  sinusi7s,  visit:  www.MySinusi7s.com.   ©2016  Intersect  ENT,  Inc.  All  rights  reserved.  INTERSECT  and  PROPEL  are  trademarks  and  registered  trademarks  of  Intersect  ENT,  Inc.    MySinusi7s.com  is  a  trademark  of  Intersect  ENT,  Inc.   MPM  00114  Rev.  B